Significance of an Epidermal Growth Factor Receptor Mutation in Cerebrospinal Fluid for Carcinomatous Meningitis

Nobuhiro Kanaji¹, Shuji Bandoh¹, Norihiro Nagamura¹, Yoshio Kushida², Reiji Haba² and Toshihiko Ishida¹

Abstract

We report a case of epidermal growth factor receptor (EGFR) inhibitor-sensitive lung adenocarcinoma with carcinomatous meningitis who showed a good response to gefitinib, an oral tyrosine kinase inhibitor of EGFR. This good response to gefitinib treatment was attributed to evidence of an EGFR mutation, L858R in exon 21, which was detected in a small amount of cerebrospinal fluid (CSF) before the positive CSF cytology. Patients with carcinomatous meningitis often have a poor performance status, and therefore diagnostic approaches and therapeutic methods are also often limited. Detection of EGFR mutations may be a useful method for non-small cell lung cancer diagnosis, and also facilitate determination of appropriate therapeutic protocols.

Key words: non-small cell lung cancer, epidermal growth factor receptor, carcinomatous meningitis, cerebrospinal fluid, gefitinib, mutation

(Introduced 10.2169/internalmedicine.46.0335)

Introduction

Carcinomatous meningitis is a clinically important neurological complication of systemic cancer, and often leads to a poor performance status. The prognosis for patients with carcinomatous meningitis is very poor, with a median survival of only 4 weeks (1).

Gefitinib (Iressa™; AstraZeneca, Wilmington, DE) is an oral tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), and large clinical trials have demonstrated its anticancer activity in patients with non-small cell lung cancer (NSCLC) (2, 3). It has also been reported that mutations of the EGFR gene can predict prolonged survival after gefitinib treatment in patients with NSCLC (4, 5). Several case reports have indicated that gefitinib may also be effective against carcinomatous meningitis (6-8).

We report a NSCLC patient with carcinomatous meningitis, in whom an EGFR mutation was detected that brought about a good clinical response to gefitinib treatment. To the best of our knowledge, this is the first report demonstrating evidence of an EGFR mutation in cerebrospinal fluid (CSF). Furthermore, this case suggests that an EGFR mutation can be detected in a small amount of CSF, despite negative cytology.

Case Report

A 72-year-old man was admitted to our hospital in January 2007 for further evaluation of disturbance of consciousness that had gradually progressed for 1 month. His consciousness level was in the twilight state, and he was completely unable to express his intentions. There was no fever elevation. He had smoked about 20 cigarettes for 50 years.

Head computed tomography (CT) revealed dilatation of the cerebral ventricles, periventricular low density and enhancement on the brain surface (Fig. 1A), suggesting meningitis, especially carcinomatous meningitis, together with his clinical course. A chest X-ray showed a nodule in the right middle lung field, and CT revealed a 3-cm tumor with i-
Figure 1. (A) Head CT shows enhancement of the brain surface, indicating carcinomatous meningitis (arrow). (B) Chest CT shows primary lung cancer in the right upper lobe (arrow) and aspiration pneumonia in the left S6 area (arrowhead). (C) There is no abnormal uptake of F18-fluorodeoxyglucose except for the primary lesion (arrow) on positron emission tomography.

regional edges in the right upper lobe (Fig. 1B), suggesting lung adenocarcinoma. Aspiration pneumonia due to his deteriorated consciousness was also recognized (Fig. 1B). Abnormal F18-fluorodeoxyglucose uptake (SUV 6.7) into the tumor was seen on positron emission tomography scanning, and there was no other abnormal uptake into the lesion (Fig. 1C). The serum carcinoembryonic antigen (CEA) level was 1.5 ng/ml and within the normal range. Although primary lung cancer with carcinomatous meningitis was highly suspected, a bronchoscopic approach could not be performed because of his twilight state. Lumbar punctures were performed to diagnose the cause of the disturbance of consciousness. The cerebrospinal pressure was 18 mmH2O and the cell number in the CSF was slightly increased to 21 μ/lml. The CEA level in the CSF was 6.1 ng/ml, which was 4-fold higher than the serum CEA level. Although two lumbar punctures were performed and each 3-ml CSF sample was examined for cytodiagnosis, two clinical pathologists did not diagnose a cancerous lesion. No microorganisms, including Mycobacterium tuberculosis, were identified in the CSF. In a third lumbar puncture, carcinomatous meningitis was established by positive cytology for malignant cells consistent with metastatic adenocarcinoma (Fig. 2). He was diagnosed as lung cancer with carcinomatous meningitis (cT1N0M1, stage IV).

We obtained informed consent for genetic analysis from the patient’s family and analyzed the EGFR status in the CSF obtained from the first lumbar puncture. Total ribonucleic acid (RNA) was extracted from the cells in 0.5 ml of the CSF sample using a QIAamp RNA Blood Mini Kit (Qiagen, Hilden, Germany), and 40 μl of complementary de-
oxiribonucleic acid (cDNA) was synthesized using an oligo dT primer and SuperScript II RNaseH-Reverse Transcriptase (Invitrogen, Carlsbad, CA). The sequences of the gene-specific primers for the reverse transcription-polymerase chain reaction (RT-PCR) were as follows: F1, 5'-AGCTTGTGGAGCCTCTTACACC-3'; R1, 5'-TAAAATTGATTCCAATGCCATCC-3'; F2, 5'-TCCTCGATGAAGCCTACGTGA-3'; R2, 5'-TGCCTCCTTCTGCATGGTATT-3'. The first PCR was performed using primers F1 and R1 followed by the second PCR using primers F2 and R2. The nested PCR was performed using Ready-To-Go PCR beads (Amersham Biosciences UK Ltd., Buckinghamshire, UK). Briefly, 1 μl of each primer (10 μM), 1 μl of cDNA and 22 μl of distilled water were added to the PCR beads. The PCR amplification comprised of 30 cycles of denaturation at 94°C for 30 seconds, annealing at 48°C (55°C in the second PCR) for 30 seconds and extension at 72°C for 1 minute. The second PCR product was a 348-bp fragment. The EGFR mutation in the patient’s CSF sample was examined using PCR-based direct sequencing. The DNA bands were isolated from the gel, purified and sequenced using the PRISM dye terminator cycle sequencing method and an ABI PRISM 310 Genetic Analyzer version 3.4.5 (Applied Biosystems, Foster City, CA). As a result, the L858R mutation in exon 21 was confirmed to be present in the patient’s CSF sample (Fig. 3). The other EGFR mutations were not detected (data not shown).

Since his Eastern Cooperative Oncology Group performance status was 4, conventional intravenous chemotherapy was considered to be risky. On the other hand, the presence of EGFR mutation was evident. Although gefitinib therapy could not be allowed for the first therapy, he was treated with gefitinib (250 mg/day) with his family’s agreement. After 2 weeks, his consciousness level had improved significantly. After 2 months, his consciousness became alert, and the primary lesion was markedly regressed (Fig. 4). The clinical effectivenessto gefitinib treatment was a partial response.

**Discussion**

The present case suggests that gefitinib may be a powerful therapeutic option for carcinomatous meningitis in NSCLC patients. To the best of our knowledge, this is the first report to show a positive association between the evidence of an EGFR mutation in the CSF and a great benefit of gefitinib treatment for carcinomatous meningitis.

Carcinomatous meningitis is often found in patients with metastatic malignancies, and can also be the initial manifestation of an underlying malignancy (9). Although the diagnosis can generally be made by cytologic examination of the CSF, it has been reported that the initial cytologic examination is only diagnostic in approximately 50% of the cases (10). In the present case, the EGFR mutation was identified in the first CSF, despite negative CSF cytology. Among lung cancers, the most frequently involved histological types are adenocarcinoma and small cell lung cancer (1), and EGFR mutations are seen in the majority of adenocarcinomas (4). Since the consciousness level and performance status of patients with carcinomatous meningitis are frequently deteriorated, as in the present case, bronchoscopy often cannot be performed. Therefore, the detection of EGFR mutations in
the CSF may help a diagnosis of lung cancer with carcinomatous meningitis. Although a recent study reported that EGFR mutations were also detected in esophageal and pancreatic adenocarcinomas (11), the present case showed typical radiological findings of a well-differentiated lung adenocarcinoma, suggesting that the metastatic carcinomatous meningitis was caused by the lung cancer.

The detection of EGFR mutations is not limited to a diagnosis of lung cancer, but can also lead to the use of optimal therapeutic methods, such as the choice of an EGFR inhibitor. The treatments for carcinomatous meningitis include radiotherapy, systemic chemotherapy and intrathecal chemotherapy with methotrexate, thiopeta and cytarabine (12). However, there is no established treatment. EGFR inhibitor treatment was reported to be effective in 24 of 29 patients with EGFR mutations, compared with 2 of 21 patients without mutations (4). The present case suggests that the presence of an EGFR mutation in the CSF may predict a good response to EGFR inhibitor administration in patients with carcinomatous meningitis. There have been several other case reports showing the efficacy of gefitinib for carcinomatous meningitis (6-8) as well as brain metastasis (13-15). EGFR inhibitors may become a new therapeutic option for carcinomatous meningitis. On the other hand, gefitinib may cause a serious adverse effect such as interstitial lung disease. It has been reported that gefitinib-induced interstitial lung disease was significantly associated with man sex, a ease. It has been reported that gefitinib-induced interstitial lung disease (17). In the present case, smoking history, sex, and poor performance status were risk factors of gefitinib-induced interstitial lung disease. The analysis of EGFR mutation may be very important to determine whether treatment for EGFR inhibitor is proper or not. Another suggestive finding in the present case was the elevated CEA level in the CSF. Several reports have demonstrated increased CEA levels in the CSF of most patients with carcinomatous meningitis arising from several kinds of cancer (18, 19). There are two possible mechanisms to explain the elevation of CEA in the CSF: (i) CEA is locally produced by cancer cells; and (ii) CEA is passively transferred by the serum, due to elevated serum CEA levels and/or blood-CSF-barrier disturbance (18). In the present case, the CEA level in the CSF was 4-fold higher than the serum CEA level. This finding suggests that cancer cells in the CSF may produce CEA. In other words, cancer cells are present in the CSF. Although the increased CEA level in the CSF may suggest carcinomatous meningitis, it is not specific for lung cancer, and does not provide any information regarding the therapeutic strategy, including the prediction of effectiveness for EGFR inhibitor administration.

In conclusion, the evidence of an EGFR mutation in the CSF may help a diagnosis of lung cancer with carcinomatous meningitis and predict a good response to EGFR inhibitor treatment. In patients with a poor performance status, who are suspected of having lung cancer with carcinomatous meningitis, analysis of EGFR mutations in the CSF may be a very useful method to resolve two problems at one time.

**References**


